BioVersys AG

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the companys award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address...

Antibiotic resistance,small molecules,nosocomial infections,tuberculosis,amr,and r&d

Bioversys ag operates in the Biotechnology research industry.

Bioversys ag's revenue is 1m - 10m

Bioversys ag has 11 - 50 employees.